P
Philippe Pflieger
Researcher at Hoffmann-La Roche
Publications - 37
Citations - 562
Philippe Pflieger is an academic researcher from Hoffmann-La Roche. The author has contributed to research in topics: Temperature homeostasis & Dalcetrapib. The author has an hindex of 14, co-authored 37 publications receiving 550 citations.
Papers
More filters
Journal ArticleDOI
Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport.
Eric J. Niesor,Christine Magg,Naoto Ogawa,Hiroshi Okamoto,Elisabeth von der Mark,Hugues Matile,Georg Schmid,Roger G. Clerc,Evelyne Chaput,Denise Blum-Kaelin,Walter Huber,Ralf Thoma,Philippe Pflieger,Makoto Kakutani,Daisuke Takahashi,Gregor Dernick,Cyrille Maugeais +16 more
TL;DR: Modulation of CETP activity by dalcetrapib does not inhibit CETP-induced pre-β-HDL formation, which may be required to increase reverse cholesterol transport.
Journal ArticleDOI
Pyrimido[1,6-a]benzimidazoles: a new class of DNA gyrase inhibitors.
Christian Hubschwerlen,Philippe Pflieger,Jean-Luc Specklin,Klaus Gubernator,Hans Gmuender,Peter Angehrn,Ivan Kompis +6 more
TL;DR: Pyrimido[1,6-alpha]benzimidazoles 11 have been found to be a new class of inhibitors of this enzyme.
Journal ArticleDOI
Mechanisms underlying off-target effects of the cholesteryl ester transfer protein inhibitor torcetrapib involve L-type calcium channels.
Roger G. Clerc,Andrea Stauffer,Franziska Weibel,Emmanuelle Hainaut,Anne Perez,Jean-Christophe Hoflack,Agnès Bénardeau,Philippe Pflieger,Jose Mr Garriz,John W. Funder,Alessandro M. Capponi,Eric J. Niesor +11 more
TL;DR: The unique steroidogenic and hypertensive side effects of torcetrapib may be linked and involve voltage-gated L-type Ca2+ channels, suggesting initially divergent pathways.
Patent
Heteroaryl and benzyl amide compounds
Aurelia Conte,Holger Kuehne,Thomas Luebbers,Patrizio Mattei,Cyrille Maugeais,Werner Mueller,Philippe Pflieger +6 more
TL;DR: In this paper, the authors defined a set of pharmaceutically acceptable compounds of formula I, where R1, R2, R4, R5, A, B, D, and n are defined, and processes for their preparation, their use as pharmaceuticals and pharmaceutical compositions comprising them.
Patent
Substituted benzamide derivatives
TL;DR: In this paper, it has been found that the compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1, and the compounds may be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, schizophrenia, neurological diseases such as Parkinsons disease, neurodegenerative disorders such as Alzheimers disease, Alzheimer disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders, disorders and malfunction of body temperature homeostasis